ERAP1 Inhibitors

The chemical class known as ERAP1 Inhibitors includes a range of compounds that indirectly affect the activity of Endoplasmic Reticulum Aminopeptidase 1, an enzyme integral to antigen processing and presentation. These inhibitors generally do not target ERAP1 directly but instead modulate its function by influencing related biochemical pathways or cellular processes. Key to this class are compounds that affect the zinc-dependency of ERAP1, such as Zinc Chloride, EDTA, and 1,10-Phenanthroline. These chemicals can alter the enzyme's activity by disrupting its zinc-dependent catalytic site, thereby influencing its peptide-trimming function.

Another significant aspect of these inhibitors is their role in modulating the availability of peptide substrates for ERAP1. Proteasome inhibitors like MG132, Lactacystin, and Bortezomib play a crucial role in this regard. By inhibiting the proteasome, these compounds can alter the pool of peptides available for ERAP1 to process, indirectly affecting its function. Additionally, inhibitors of other proteases, such as Bestatin, Amastatin, Leupeptin, E-64, and Pepstatin A, also contribute to this modulation. These compounds inhibit various aminopeptidases and proteases, thereby potentially altering the peptide repertoire presented for ERAP1 trimming.